Response to the letter by Dr. Demetrios Moris “Reply to Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel”

“Aspirin resistance” is a poor pharmacological term which should be used when aspirin is unable to hit its molecular target – the platelet cyclooxygenase (COX)-1. However, this type of resistance is rare and in the range of 1% or less [1–2]. This term frequently mixed up with clinical treatm ent failure in an inappropriate way [3]. Therefore, patients with poor aspirin response should not be considered resistant or non-resistant. Using “aspirin treatment failure” may be more appropriate.

Source: Journal of the Neurological Sciences - October 31, 2016 Category: Neurology Authors: Yingting Wang, Huan Cai, Guoqing Zhou, Zhizhong Zhang, Xinfeng Liu Tags: Response to Letter to the Editor Source Type: research